- Sarepta plans Elevidys shipments despite FDA request (SRPT) Seeking Alpha
- Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidys The New York Times
- FDA Requests Sarepta Therapeutics Suspend Distribution of Elevidys and Places Clinical Trials on Hold for Multiple Gene Therapy Products Following 3 Deaths fda.gov
- We are mothers of Duchenne patients. Recent setbacks with Sarepta must not stop progress statnews.com
- Sarepta Therapeutics Stock Plunges After Another Patient Death Is Linked to One of Its Gene Therapies The Wall Street Journal
Source link
